Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study | Zendy

Anton Hagenbeek | Zendy; Hans L. Mooij | Zendy; Josée M. Zijlstra | Zendy; Pieternella J. Lugtenburg | Zendy; Gustaaf van Imhoff | Zendy; Marcel Nijland | Zendy; Sanne H. Tonino | Zendy; Martin Hutchings | Zendy; Marjolein Spiering | Zendy; Roberto Liu | Zendy; Harm van Tinteren | Zendy; Marie José Kersten | Zendy

Open Access

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

Author(s) -

Anton Hagenbeek,

Hans L. Mooij,

Josée M. Zijlstra,

Pieternella J. Lugtenburg,

Gustaaf van Imhoff,

Marcel Nijland,

Sanne H. Tonino,

Martin Hutchings,

Marjolein Spiering,

Roberto Liu,

Harm van Tinteren,

Marie José Kersten

Publication year - 2018

Publication title -

haematologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.782

H-Index - 142

eISSN - 1592-8721

pISSN - 0390-6078

DOI - 10.3324/haematol.2018.196899

Subject(s) - brentuximab vedotin , medicine , salvage therapy , refractory (planetary science) , cytarabine , dexamethasone , carmustine , oncology , cisplatin , lymphoma , de escalation , chemotherapy , hodgkin lymphoma , etoposide , physics , astrobiology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog